Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Helping Patients Avoid Treatment-Related Nausea

December 1, 1999
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 12
Volume 8
Issue 12

NEW YORK-Patients may talk about many treatment issues with their doctors but keep mum about treatment-related nausea. “When they go to their chemotherapy nurse, that’s when they say, ‘It was awful. I was sick for 3 days after chemotherapy,’” Terri Maxwell, RN, MSN, said at a teleconference sponsored by Cancer Care Inc.

NEW YORK—Patients may talk about many treatment issues with their doctors but keep mum about treatment-related nausea. “When they go to their chemotherapy nurse, that’s when they say, ‘It was awful. I was sick for 3 days after chemotherapy,’” Terri Maxwell, RN, MSN, said at a teleconference sponsored by Cancer Care Inc.

Cancer patients often say in surveys that treatment-related nausea and vomiting are among their worst problems. “Yet, in most cases, these problems can be controlled or prevented by medication and an individualized approach,” said Ms. Maxwell, executive director, Center for Palliative Care, Thomas Jefferson University, Philadelphia.

The best approach is prevention, she said, and that requires determining who is most at risk. “I think it’s important for those of us who are giving these treatments to take an individual look at our patients and recognize some of the patient-related factors that might make somebody more susceptible to treatment-related nausea and vomiting,” Ms. Maxwell commented.

Premenopausal women experience more nausea and vomiting than men or postmenopausal women, Ms. Maxwell noted, and patients who are highly anxious because of previous bouts of severe nausea and vomiting are also at greater risk. So are those with a history of motion sickness and women who experienced severe vomiting during pregnancy. However, people over age 50 and people who have a history of high daily alcohol intake are at lower risk.

Factors that can exacerbate treatment-related nausea and vomiting include dehydration, delayed stomach emptying caused by bowel obstruction, severe fatigue, unrelieved pain, narcotic analgesia, and some nonsteroidal anti-inflammatory drugs (NSAIDs).

In general, the quicker the chemotherapy is administered, the more likely it is to cause symptoms. Radiation does not usually cause nausea and vomiting, Ms. Maxwell pointed out, unless the person is having radiation treatment to the epigastric area. In these patients, symptoms generally occur an hour or two after treatment and can usually be prevented with antinausea medication taken about a half hour before radiation and sometimes repeated later in the afternoon or evening.

Colon cancer patients or gynecologic cancer patients who are receiving radiation in the pelvic area may get diarrhea but will not have nausea related to the radiation, she said.

The acute form of nausea occurs within the first 24 hours after chemotherapy or radiation. The serotonin antagonists, ondansetron (Zofran), granisetron (Kytril), and dolasetron (Anzemet), are approved to prevent this form and are given prior to chemotherapy. Using these agents to treat the delayed form is still controversial and under investigation.

“The oral forms of the serotonin antagonists are just as effective as the IV forms and are ideal for home use,” Ms. Maxwell said. Clinics will sometimes use the IV form because of reimbursement issues, she noted.

There are only a few side effects associated with the serotonin antagonists, she said. They may cause headache, she said, and, over a 7-day period, some constipation.

Their biggest drawback, Ms. Maxwell observed, is that they are very expensive. “They are for use only with those chemotherapy regimens that are known to cause significant nausea,” she added.

She pointed out that drugs such as prochlorperazine (Compazine and generics), thiethylperazine (Torecan), and promethazine (Phenergan and others) are less expensive and can be effective when used with chemotherapy regimens with mild-to-moderate emetogenic potential.

These agents can be a bit more sedating, she said, “and sometimes patients don’t like taking them quite as much because they feel sleepy on them. But they can be extremely helpful and work in a different way than Kytril, Zofran, and Anzemet. Sometimes you need to use both kinds of agents.”

The delayed form of chemotherapy-induced nausea is the most difficult to manage, Ms. Maxwell said. It occurs the day after treatment and can last up to 5 days. It is only associated with a few drugs, including cisplatin (Platinol) and carboplatin (Paraplatin).

Antinausea regimens in the delayed setting are still evolving. Ms. Maxwell said that some clinicians have tried granisetron, usually in combination with a drug like prochlorperazine and IV dexamethasone. She cautioned that if nausea develops the day after treatment, patients should take their antinausea medication as soon as it develops. Waiting until the nausea is stronger will just make it more difficult to treat.

The anticipatory type of nausea develops when the other types have not been well managed, a classic conditioned response to the stimuli surrounding therapy. Ms. Maxwell told a story about a patient who ran into her chemotherapy nurse at the mall and promptly threw up.

Usually, anticipatory nausea is treated with antianxiety agents prior to the appointment; the one most often prescribed is lorazepam (Ativan and generics).

Cancer patients also need to know that their nausea can arise from other things. “Patients have called thinking they were sick from their chemotherapy when, in actuality, they had a GI virus,” Ms. Maxwell said, “so carefully assessing the nausea and questioning the patient about other possible causes is important.”

Tips for Cancer Patients to Avoid Treatment-Related Nausea and Vomiting

Do not arrive for chemotherapy hungry.

Limit (but do not eliminate) food intake on the day of therapy. It may not stop the nausea but it may prevent developing food aversions.

Use lemon drops. They reduce nausea by cutting the flow of saliva.

Eat whatever tastes good to you.

Try to eat foods that taste good cold. The odor of hot foods can lead to nausea in susceptible people.

Do not prepare food yourself. Buy prepared food or have someone else prepare it.

Finally, Ms. Maxwell provided some basic tips for avoiding treatment-related nausea and vomiting that nurses can offer patients (see Table above).

Articles in this issue

SWOG to Study Docetaxel/Estramustine in Advanced Prostate Cancer
US Smoking Rates No Longer Falling, Due to More Young Smokers
Americans Favor Higher Cigarette Tax to Balance the Budget
Saint Vincents Hospital Opens Comprehensive Cancer Center
New Breast Biopsy Techniques Allow ‘One-Stop’ Procedures
Director of NCI Mentioned as a Candidate to Head NIH
Challenges in Designing Chemoprevention Trials
Black Women Underrepresented in Breast Cancer Trials
UnitedHealthcare Plan Gives Physicians Final Say on Care
New Agents, Sequential Schedules Hold Promise
Half-Day Workshop Can Improve Cancer Team’s Communication Skills
The Search for Better SERMs Continues
Four SPORE Grants Will Support Ovarian Cancer Research
$70 Million Will Fund Tobacco Study Centers at Seven Universities
Cancer Risk of Veterans Exposed to Nuclear Weapons Tests Unresolved

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Event-free survival benefit was observed among BCG-naïve patients with carcinoma in situ undergoing treatment with sasanlimab plus BCG.
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Related Content

Data from the phase 3 KEYNOTE-689 trial support the approval of the pembrolizumab-based regimen in this locally advanced HNSCC population.

FDA Approves Perioperative Pembrolizumab Plus Radiation in HNSCC

Russ Conroy
June 12th 2025
Article

Data from the phase 3 KEYNOTE-689 trial support the approval of the pembrolizumab-based regimen in this locally advanced HNSCC population.


An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.


The VIALE-A trial showed high activity with revumenib plus azacitidine and venetoclax for patients with NPM1m/KMT2Ar AML.

Revumenib Plus Azacitidine/Venetoclax Appears Safe in Older NPM1/KMT2Ar AML

Ariana Pelosci
June 12th 2025
Article

The VIALE-A trial showed high activity with revumenib plus azacitidine and venetoclax for patients with NPM1m/KMT2Ar AML.


Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Mike Lattanzi, MD;Damian N. Sorce, MD
June 5th 2025
Podcast

Experts weigh in on the practical applications of PSMA PET imaging


FDA Grants Fast Track Designation to RAD101 Imaging for Brain Metastases

FDA Grants Fast Track Designation to RAD101 Imaging for Brain Metastases

Tim Cortese
June 12th 2025
Article

The developer plans to share topline results for RAD101 in various solid tumors from the supporting phase 2b trial in the second half of 2025.


In patients 39 years and younger, a statistically significant association between colorectal cancer diagnosis and endometriosis was not observed.

Adverse Sexual Health Outcomes Appear More Likely in Women With CRC

Roman Fabbricatore
June 12th 2025
Article

In patients 39 years or younger, a statistically significant association between colorectal cancer diagnosis and endometriosis was not observed.

Related Content

Data from the phase 3 KEYNOTE-689 trial support the approval of the pembrolizumab-based regimen in this locally advanced HNSCC population.

FDA Approves Perioperative Pembrolizumab Plus Radiation in HNSCC

Russ Conroy
June 12th 2025
Article

Data from the phase 3 KEYNOTE-689 trial support the approval of the pembrolizumab-based regimen in this locally advanced HNSCC population.


An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.


The VIALE-A trial showed high activity with revumenib plus azacitidine and venetoclax for patients with NPM1m/KMT2Ar AML.

Revumenib Plus Azacitidine/Venetoclax Appears Safe in Older NPM1/KMT2Ar AML

Ariana Pelosci
June 12th 2025
Article

The VIALE-A trial showed high activity with revumenib plus azacitidine and venetoclax for patients with NPM1m/KMT2Ar AML.


Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Mike Lattanzi, MD;Damian N. Sorce, MD
June 5th 2025
Podcast

Experts weigh in on the practical applications of PSMA PET imaging


FDA Grants Fast Track Designation to RAD101 Imaging for Brain Metastases

FDA Grants Fast Track Designation to RAD101 Imaging for Brain Metastases

Tim Cortese
June 12th 2025
Article

The developer plans to share topline results for RAD101 in various solid tumors from the supporting phase 2b trial in the second half of 2025.


In patients 39 years and younger, a statistically significant association between colorectal cancer diagnosis and endometriosis was not observed.

Adverse Sexual Health Outcomes Appear More Likely in Women With CRC

Roman Fabbricatore
June 12th 2025
Article

In patients 39 years or younger, a statistically significant association between colorectal cancer diagnosis and endometriosis was not observed.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.